Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?

Published on Jan 2, 2016in Expert Opinion on Drug Safety3.383
· DOI :10.1517/14740338.2016.1112375
Giuseppe Murdaca31
Estimated H-index: 31
,
Francesca Spanò14
Estimated H-index: 14
+ 4 AuthorsFrancesco Puppo45
Estimated H-index: 45
Sources
Abstract
Introduction: TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying antirheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated diseases such as rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis, psoriasis and/or psoriatic arthritis, and may be administered off-label to treat disseminated granuloma annulare systemic lupus erythematosus and systemic sclerosis. There are several TNF-α inhibitors available for clinical use including infliximab, adalimumab, golimumab, certolizumab pegol and etanercept.Areas covered: infliximab and adalimumab can induce the development of anti-infliximab (anti-IFX) and anti-adalimumab (anti-ADA) monoclonal antibodies (mAbs). In this review, we discuss the impact of anti-IFX and anti-ADA mAbs upon efficacy and safety of these biological agents.Expert opinion: IgG/IgE neutralizing antibodies against infliximab and adalimumab decrease the possibility of achieving a minimal disease activity s...
📖 Papers frequently viewed together
11 Citations
1 Citations
1 Citations
References90
Newest
#1Giuseppe MurdacaH-Index: 31
#2Francesca Spanò (UniGe: University of Genoa)H-Index: 14
Last. Francesco PuppoH-Index: 45
view all 7 authors...
Introduction: TNF-α is a pro-inflammatory cytokine known to a have a key role in the pathogenesis of chronic immune-mediated diseases. TNF-α inhibitors can be administered either as monotherapy or in combination with other anti-inflammatory or disease-modifying anti-rheumatic drugs (DMARDs) to treat chronic immune-mediated diseases.Areas covered: Patients receiving TNF-α inhibitors are at high risk of infections. Based on our experience, in this paper, we discuss the risk of infections associate...
113 CitationsSource
#1Meghna Jani (MAHSC: Manchester Academic Health Science Centre)H-Index: 13
#2Hector Chinoy (MAHSC: Manchester Academic Health Science Centre)H-Index: 33
Last. Anne Barton (MAHSC: Manchester Academic Health Science Centre)H-Index: 76
view all 10 authors...
Abstract Background Up to 40% of patients with rheumatoid arthritis treated with anti-tumour necrosis factor (TNF) drugs do not respond because of primary inefficacy or loss of response. Although one explanation is that immunogenicity leads to the development of anti-drug antibodies and low drug concentrations, the clinical usefulness of pharmacological monitoring is debated. Our aim was to assess whether the presence of anti-drug antibodies and non-trough drug concentrations could predict treat...
12 CitationsSource
#1Giuseppe MurdacaH-Index: 31
#2Francesca Spanò (UniGe: University of Genoa)H-Index: 14
Last. Francesco PuppoH-Index: 45
view all 6 authors...
Introduction: During the last decade, many new biological immune modulators have entered the market as new therapeutic principles. Biologics, including TNF-α inhibitors, are the new frontier in the treatment of immune-mediated or inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, Crohn’s disease, ankylosing spondylitis, systemic sclerosis, disseminated granuloma annulare, psoriasis and/or psoriatic arthritis. TNF-α inhibitors have demonstrated efficacy and are wel...
32 CitationsSource
#1Giuseppe Murdaca (UniGe: University of Genoa)H-Index: 31
#2Rossella Gulli (UniGe: University of Genoa)H-Index: 13
Last. Francesco Puppo (UniGe: University of Genoa)H-Index: 45
view all 5 authors...
Enabling Technology, Genomics, Proteomics Clinical Development Phases I-III Regulatory, Quality, Manufacturing There are five tumor necrosis factor alpha (TNF-α) inhibitors available for clinical use that have demonstrated efficacy as monotherapy or in combination with other anti-inflammatory or disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of immune-mediated diseases. These include the anti-TNF-α monoclonal antibodies infliximab, adalimumab, golimumab, and certolizumab pegol,...
11 CitationsSource
#1Giuseppe Murdaca (UniGe: University of Genoa)H-Index: 31
#2Rossella Gulli (UniGe: University of Genoa)H-Index: 13
Last. Francesco Puppo (UniGe: University of Genoa)H-Index: 45
view all 8 authors...
The tumor necrosis factor-α ( TNF-α ) gene has been proposed as a major candidate gene in psoriatic arthritis (PsA). TNF-α is a therapeutic target for patients responding poorly to conventional treatments. We investigated the role of single-nucleotide polymorphisms (SNPs) at positions -238, -308, and +489 of the TNF-α gene in the genetic susceptibility to PsA, in the severity of the disease, and, finally, in the response to TNF-α inhibitors (adalimumab, etanercept, or infliximab). Fifty-seven Ca...
65 CitationsSource
#1É. Pallagi-Kunstár (University of Szeged)H-Index: 3
#2Klaudia Farkas (University of Szeged)H-Index: 16
Last. Tamás Molnár (University of Szeged)H-Index: 32
view all 10 authors...
Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease
25 CitationsSource
#1Giuseppe MurdacaH-Index: 31
#2Francesca SpanòH-Index: 14
Last. Francesco PuppoH-Index: 45
view all 5 authors...
Systemic sclerosis (SSc) is a rare connective tissue disease characterized by chronic inflammation and fibrosis of the skin, vascular abnormalities and variable involvement of organs. TNF-α has a central role in initial host response to infections and in the pathogenesis of various systemic immune-mediated diseases. Serum levels of TNF-α are elevated in patients with SSc and favor the development of pulmonary fibrosis and pulmonary arterial hypertension. Inflammatory arthritis can occur in patie...
25 CitationsSource
#1Giuseppe MurdacaH-Index: 31
#2Francesca Spanò (UniGe: University of Genoa)H-Index: 14
Last. Francesco PuppoH-Index: 45
view all 6 authors...
Introduction: TNF-α inhibitors have demonstrated efficacy in large, randomized controlled clinical trials either as monotherapy or in combination with other anti-inflammatory or disease-modifying antirheumatic drugs in the treatment of chronic inflammatory immune-mediated diseases. Etanercept is a fusion protein that acts as a ‘decoy receptor’ for TNF-α. Areas covered: This paper evaluates the efficacy and safety of etanercept in patients with chronic inflammatory immune-mediated diseases. Exper...
18 CitationsSource
#1Giuseppe Murdaca (UniGe: University of Genoa)H-Index: 31
#2Francesca Spanò (UniGe: University of Genoa)H-Index: 14
Last. Francesco PuppoH-Index: 45
view all 3 authors...
Introduction: Systemic sclerosis (SSc) is a rare connective tissue disease characterized by chronic inflammation and fibrosis of the skin, vascular abnormalities and variable involvement of organs. Patients with limited SSc typically develop pulmonary arterial hypertension (PAH). TNF-α, VEGF, platelet-derived growth factor and endothelin-1 play a key role in the development of PAH. Areas covered: This paper addresses the efficacy and safety of current drugs used for the treatment of PAH. Expert ...
16 CitationsSource
#1Meghna Jani (MAHSC: Manchester Academic Health Science Centre)H-Index: 13
#2Anne Barton (MAHSC: Manchester Academic Health Science Centre)H-Index: 76
Last. Hector Chinoy (MAHSC: Manchester Academic Health Science Centre)H-Index: 33
view all 5 authors...
The management of RA, SpA, psoriasis and inflammatory bowel disease has significantly improved over the last decade with the addition of tumour necrosis factor inhibitors (anti-TNFs) to the therapeutic armamentarium. Immunogenicity in response to monoclonal antibody therapies (anti-drug antibodies) may give rise to low serum drug levels, loss of therapeutic response, poor drug survival and/or adverse events such as infusion reactions. To combat these, the use of concomitant MTX may attenuate the...
147 CitationsSource
Cited By54
Newest
Tumor necrosis factor (TNF) is a regulator of several chronic inflammatory diseases, such as rheumatoid arthritis. Although anti-TNF biologics have been used in clinic, they render several drawbacks, such as patients’ progressive immunodeficiency and loss of response, high cost, and intravenous administration. In order to find new potential anti-TNF small molecule inhibitors, we employed an in silico approach, aiming to find natural products, analogs of Ampelopsin H, a compound that blocks the f...
Source
During this pandemic, dermatological infusion centers were partially unavailable, suspended or even reconverted to guest COVID-19 patients, consequently infliximab (IFX) infusions became challenging for their both logistic arrangement and also for patients' COVID-19 phobia. This 48 weeks follow-up retrospective observational study included 37 PsO patients that underwent IFX SB2 during pandemic in two primary dermatological referral centers. In 23 (62.1%) we had to switch from IFX to other biolog...
Source
Source
#1Meenu Wadhwa (NIBSC: National Institute for Biological Standards and Control)H-Index: 28
#2Chris Bird (NIBSC: National Institute for Biological Standards and Control)H-Index: 17
Last. Peter Rigsby (NIBSC: National Institute for Biological Standards and Control)H-Index: 17
view all 5 authors...
Adalimumab products continue to widen patient access and reduce costs with substantial benefit to healthcare systems. However, their sustainability and long-term success is highly dependent on maintaining quality, safety and efficacy while minimizing any risk of divergence during evolution. In recognition of this need, the World Health Organization in 2019 established the 1st International Standard (IS) for Adalimumab with defined units for individual bioactivities. Two candidate standards were ...
1 CitationsSource
#1Bruno BonazH-Index: 38
#2Valérie SinnigerH-Index: 16
Last. Sonia PellissierH-Index: 16
view all 3 authors...
The vagus nerve is a mixed nerve, comprising 80% afferent fibers and 20% efferent fibers. It allows a bidirectional communication between the central nervous system and the digestive tract. It has a dual anti-inflammatory properties via activation of the hypothalamic pituitary adrenal axis, by its afferents, but also through a vago-vagal inflammatory reflex involving an afferent (vagal) and an efferent (vagal) arm, called the cholinergic anti-inflammatory pathway. Indeed, the release of acetylch...
2 CitationsSource
#1Guoying Cao (Fudan University)H-Index: 9
#2Jicheng Yu (Fudan University)H-Index: 8
Last. Xiaoli Yang (Fudan University)H-Index: 1
view all 7 authors...
A comparison of the immunogenicity, safety, and pharmacokinetic properties of HS016 and its originator, adalimumab, was conducted in Chinese healthy male subjects. This was a phase 1 single-center, randomized, parallel-group double-blind clinical trial. Chinese healthy male subjects (1:1) allocated to HS016 and adalimumab groups were treated with single subcutaneous injections (40 mg/0.8 mL). The pharmacokinetic equivalence of HS016 and adalimumab was assessed by (1) the area under the plasma co...
3 CitationsSource
Abstract Background/objective SSS07, a humanized rabbit monoclonal antibody, can selectively block human tumor necrosis factor-α (TNF-α). The objective of this study was to assess the safety, tolerability, and relative immunogenicity of SSS07 after multiple single subcutaneous (SC) doses in healthy volunteers. Methods A total of 71 healthy volunteers were randomized to six sequential ascending-dose groups (5, 15, 30, 50, 75, and 100 mg), and except for the 100 mg group that only had one subject ...
Source
#1Pepijn W. A. Thomas (Radboud University Nijmegen)H-Index: 1
#2Gerben FerwerdaH-Index: 30
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 16
view all 4 authors...
Recently, ustekinumab has been approved for the treatment of Crohn's disease and ulcerative colitis. Treatment is started with an intravenous induction dose, followed by a subcutaneous dosage. We present three patients with therapy-refractory Crohn's disease, who experienced an immediate infusion reaction to intravenous administration of ustekinumab. In two of these patients a subsequent reaction to subcutaneous injections occurred. Clinical features and pathophysiology are discussed.
1 CitationsSource
#1John M Bridges (UAB: University of Alabama at Birmingham)
#2Matthew L. Stoll (UAB: University of Alabama at Birmingham)H-Index: 26
Juvenile spondyloarthritis is a subset of juvenile idiopathic arthritis (JIA) with onset in late childhood and adolescence and a strong association with human leukocyte antigen (HLA) B-27 positivity and familial aggregation that has the potential for axial involvement, potentially leading to ankylosing spondylitis. Current therapy for severe disease relies heavily on tumor necrosis factor inhibitors (TNFi). Treatment paradigms in children largely consist of extrapolation from studies on adults w...
1 CitationsSource
#1Jin-Xian Huang (HKU: University of Hong Kong)H-Index: 4
#2Yung-Heng LeeH-Index: 2
Last. James Cheng-Chung Wei (CSMU: Chung Shan Medical University)H-Index: 28
view all 3 authors...
Ixekinumab (IXE) is a high affinity IgG4 approved for the treatment of ankylosing spondylitis (AS). Recently, two phase III randomized clinical trials (COAST-V, COAST-W) showed significant and sust...
1 CitationsSource